Viatris Inc.

XTRA:VIA Stock Report

Market Cap: €14.2b

Viatris Valuation

Is VIA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VIA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VIA (€11.88) is trading below our estimate of fair value (€56.9)

Significantly Below Fair Value: VIA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VIA?

Key metric: As VIA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VIA. This is calculated by dividing VIA's market cap by their current revenue.
What is VIA's PS Ratio?
PS Ratio1x
SalesUS$15.05b
Market CapUS$14.80b

Price to Sales Ratio vs Peers

How does VIA's PS Ratio compare to its peers?

The above table shows the PS ratio for VIA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.9x
BAYN Bayer
0.4x1.0%€18.6b
MRK Merck KGaA
2.9x4.2%€59.9b
DMP Dermapharm Holding
1.7x4.1%€2.0b
PSG PharmaSGP Holding
2.5x7.3%€287.8m
VIA Viatris
1x-1.1%€14.8b

Price-To-Sales vs Peers: VIA is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (1.9x).

Price to Sales Ratio vs Industry

How does VIA's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

19 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.2x3.5%
VIA Viatris
 1x-1.1%US$14.80b
VIA 1.0xIndustry Avg. 3.2xNo. of Companies19PS048121620+
19 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.2x21.6%
VIA Viatris
 1x51.6%US$14.80b
No more companies

Price-To-Sales vs Industry: VIA is good value based on its Price-To-Sales Ratio (1x) compared to the European Pharmaceuticals industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is VIA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VIA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ratio2.6x

Price-To-Sales vs Fair Ratio: VIA is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (2.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VIA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€11.88
€12.80
+7.7%
8.7%€14.27€11.42n/a8
Dec ’25€12.52
€12.61
+0.7%
8.6%€14.20€11.36n/a8
Nov ’25€10.75
€11.82
+10.0%
9.7%€13.74€10.08n/a8
Oct ’25€10.46
€11.82
+13.0%
9.7%€13.74€10.08n/a8
Sep ’25€10.81
€11.82
+9.3%
9.7%€13.74€10.08n/a8
Aug ’25€11.07
€11.63
+5.0%
10.3%€13.79€10.11n/a8
Jul ’25€9.89
€11.43
+15.6%
6.9%€12.91€10.14n/a8
Jun ’25€9.66
€11.43
+18.3%
6.9%€12.91€10.14n/a8
May ’25€10.90
€11.65
+6.9%
7.0%€13.16€10.34n/a9
Apr ’25€10.94
€11.49
+5.1%
7.0%€12.98€10.20n/a9
Mar ’25€11.50
€11.03
-4.1%
9.6%€12.92€9.23n/a9
Feb ’25€10.77
€10.83
+0.6%
11.1%€12.93€9.23n/a9
Jan ’25€9.77
€10.52
+7.7%
12.7%€12.68€8.15n/a9
Dec ’24€8.52
€10.64
+25.0%
13.5%€12.83€8.25€12.528
Nov ’24€8.41
€11.01
+30.9%
13.9%€13.13€8.44€10.758
Oct ’24€9.44
€11.95
+26.6%
11.2%€14.16€9.44€10.469
Sep ’24€10.08
€11.36
+12.7%
12.0%€13.69€9.12€10.819
Aug ’24€9.60
€11.31
+17.9%
12.0%€13.75€9.17€11.079
Jul ’24€9.08
€11.64
+28.3%
11.9%€13.96€9.31€9.8910
Jun ’24€8.53
€11.46
+34.3%
11.8%€13.58€9.06€9.669
May ’24€8.41
€11.46
+36.3%
11.8%€13.58€9.06€10.909
Apr ’24€8.89
€12.46
+40.1%
17.3%€16.79€9.33€10.9411
Mar ’24€10.65
€12.63
+18.7%
16.7%€17.01€9.45€11.5012
Feb ’24€11.21
€12.24
+9.2%
16.9%€16.39€9.10€10.7712
Jan ’24€10.48
€12.82
+22.3%
18.2%€17.38€9.66€9.7711
Dec ’23€10.56
€12.82
+21.4%
18.2%€17.38€9.66€8.5211

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 07:44
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Viatris Inc. is covered by 44 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Ishan MajumdarBaptista Research
Richard SilverBarclays